The global Advanced Therapy Medicinal Products CDMO Market is expanding rapidly as pharmaceutical and biotechnology companies increasingly outsource the development and manufacturing of cell therapies, gene therapies, and regenerative medicines. Contract development and manufacturing organizations provide specialized capabilities covering process development, viral-vector manufacturing, analytical testing, clinical manufacturing, regulatory support, and commercial-scale production. Increasing clinical-trial activity, rising approvals of advanced therapies, and the growing complexity of manufacturing processes are strengthening demand for specialized CDMO partners.
According to Fortune Business Insights, the global advanced therapy medicinal products CDMO market was valued at USD 8.15 billion in 2025 and is projected to grow from USD 9.72 billion in 2026 to USD 39.75 billion by 2034, exhibiting a CAGR of 19.24% during the forecast period.
Why is the Advanced Therapy Medicinal Products CDMO Market Growing?
The increasing development of cell and gene therapies is one of the strongest growth drivers. Advanced therapies often require specialized manufacturing systems, highly controlled environments, sophisticated analytical testing, and extensive regulatory support that may be difficult or costly for therapy developers to build internally.
CDMOs are increasingly supporting:
The growing number of clinical programs and advanced-therapy approvals is encouraging biotechnology companies and pharmaceutical manufacturers to establish long-term partnerships with specialized CDMOs.
Key Market Trends Shaping Industry Growth
Increasing Demand for Integrated CDMO Services
A major market trend is the shift toward end-to-end CDMO solutions. Providers are increasingly offering process development, analytical testing, clinical manufacturing, commercial production, regulatory consulting, and logistics under integrated service models.
This integrated approach allows therapy developers to reduce operational complexity and manage multiple stages of development through a single manufacturing partner.